Home › DIVISIONS › Rheumatology › Current Research › Current Clinical Trials ›

Systemic Sclerosis (Scleroderma)

in

Genomic and Histological Analysis of Skin Biopsy Specimens as Biomarkers of Scleroderma and Response to Various Treatments

Primary Investigator: Monique Hinchcliff, MD

Sponsor: Eunice Kennedy Shriver national Institute of Child Health and Human Development (NICHD)

Collaborator: Dartmouth-Hitchcock Medical Center

ClinicalTrials.gov Identifier: NCT00853788

http://clinicaltrials.gov/ct2/show/NCT00853788?term=NCT00853788&rank=1

The purpose of this study is to assess whether skin biopsy specimens from patients with diffuse cutaneous systemic sclerosis (dcSSc) can be used as biomarkers (measures of activity and type) of disease to predict response to various experimental treatments.

For more information on this trial, please contact Mary Carns at 312-503-1137.

 

 

Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study-II)

Primary Investigator: John Varga, MD

Sponsor: National Heart, Lung and Blood Institute (NHLBI)

Collaborator: Hoffmann-La Roche

ClinicalTrials.gov Identifier : NCT00883129

http://clinicaltrials.gov/ct2/show/NCT00883129?term=NCT00883129&rank=1

The purpose of this study is to determine whether people with symptomatic scleroderma-related interstitial lung disease experience more respiratory benefits from treatment with a 2-year course of mycophenolate mofetil or treatment with a 1-year course of oral cyclophosphamide.

For more information on this trial, please contact Helen Donnelly at 312-503-1881.

 

The Natural History and Outcome of Patients with Scleroderma at High Risk for or with early Pulmonary Hypertension

Primary Investigator: Monique Hinchcliff, MD

Sponsor: Georgetown University

ClinicalTrials.gov Identifier: NCT00377949

http://clinicaltrials.gov/ct2/show/NCT00377949?term=NCT00377949&rank=1

The purpose of this study is to determine the timeline of progression from pre-pulmonary hypertension to diagnosable pulmonary hypertension based on right heart catheterization. Moreover, to determine the timeline for progression from diagnosable pulmonary hypertension to clinical worsening of disease as defined as death, hospitalization, or worsening of PHT symptoms.

For more information on this trial, please contact Sofia Podlusky at 312-503-1824.